Folylpolyglutamate synthetase is an enzyme that metabolizes the naturally occurring folate cofactors and all classical folate antimetabolites to forms that contain 5-6 glutamic acid residues per molecule. These metabolites do not efflux from the cell, so that polyglutamation constitutes a mechanism to metabolically trap folates in the cell. When using antifolates in the treatment of cancer, the clinician is highjacking this mechanism to deliver enzyme inhibitors to the tumor cell and trap them there, in contact with their target for a substantial period of time. This application proposes to study the two control mechanisms that determine how much folylpolyglutamate synthetase activity exists in a cell. The mouse enzyme was shown to have a feedback by long chain polyglutamates that was adapted to the particularities of mouse folate metabolism. We propose to determine whether this exists with the human enzyme and the effects of such feedback on the pharmacology of the antifolates used in cancer, namely methotrexate, raltitredid and pemetrexed. The enzymology related to this putative feedback will also be explored. The control of expression of transcription of the fpgs gene will also be studied in normal human cells and leukemia cells. The fpgs gene is expressed in primitive hematopoietic cells, then silenced during differentiation. The mechanism of this silencing will be determined and the mechanism whereby leukemic cells circumvent this control will be determined.

Public Health Relevance

The grant application proposes experiments that would lead to an understanding of how human folylpolyglutamate synthetase, an enzyme that limits the accumulation of folate compounds and analogs used for cancer therapy, carries out its functions. This enzyme determines whether individual human tumors are sensitive or insensitive to therapy with the antifolate drugs methotrexate, ralitrexid, and pemetrexed, and also the 5-fluoruracil- leucovorin combination. All of these drugs are currently used for treatment of human cancers, so any enhancement in our understanding of the enzyme that serves as a limitation for drug effects would help us design more rational cancer treatments with these drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039687-27
Application #
8601174
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
1985-09-30
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
27
Fiscal Year
2014
Total Cost
$256,953
Indirect Cost
$81,122
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Yang, Chen; Xie, Lin-Ying; Windle, Jolene J et al. (2014) Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure. FASEB J 28:1998-2008
Lawrence, Scott A; Titus, Steven A; Ferguson, Jennifer et al. (2014) Mammalian mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization of folates. J Biol Chem 289:29386-96
Bareford, M Danielle; Park, Margaret A; Yacoub, Adly et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71:4955-67
Bareford, M Danielle; Hamed, Hossein A; Tang, Yong et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy 7:1261-2
Racanelli, Alexandra C; Turner, Fiona B; Xie, Lin-Ying et al. (2008) A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression. Mol Cell Biol 28:836-48
Tomsho, John W; Moran, Richard G; Coward, James K (2008) Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase. Biochemistry 47:9040-50
Chattopadhyay, Shrikanta; Moran, Richard G; Goldman, I David (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6:404-17
Andreassi 2nd, John L; Moran, Richard G (2002) Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 41:226-35
Turner, F B; Taylor, S M; Moran, R G (2000) Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 275:35960-8
Zhao, R; Titus, S; Gao, F et al. (2000) Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275:26599-606

Showing the most recent 10 out of 18 publications